porozendoОстеопороз и остеопатииOsteoporosis and Bone Diseases2072-26802311-0716Endocrinology Research Centre10.14341/osteo12373porozendo-12373Research ArticleНаучный обзорReviewКраткое изложение проекта федеральных клинических рекомендаций по остеопорозуSummary of the Draft Federal Clinical Guidelines for Osteoporosishttps://orcid.org/0000-0003-1413-1549ГребенниковаТатьяна АлексеевнаGrebennikovaTatiana A

к.м.н., старший научный сотрудник отделения нейроэндокринологии и остеопатий

MD, PhD

Grebennikova@hotmail.comhttps://orcid.org/0000-0002-6674-6441БелаяЖанна ЕвгеньевнаBelayaZhanna E

д.м.н., профессор кафедры «Института высшего и дополнительного профессионального образования», зав. отделением нейроэндокринологии и остеопатий

MD, PhD, Professor

jannabelaya@gmail.comhttps://orcid.org/0000-0002-5634-7877МельниченкоГалина АфанасьевнаMelnichenkoGalina A.

д.м.н., проф., акад. РАН

MD, PhD, Professor

teofrast2000@mail.ruhttps://orcid.org/0000-0001-7041-0732РожинскаяЛюдмила ЯковлевнаRozhinskayaLiudmila Y.

главный научный сотрудник отделения нейроэндокринологии и остеопатий, д.м.н., проф.

MD, PhD, Professor

lrozhinskaya@gmail.comhttps://orcid.org/0000-0001-9074-2291ЦориевТимур ТамерлановичTsorievTimur T.

к.м.н., научный сотрудник

MD, PhD

timur.tsoriev@gmail.comhttps://orcid.org/0000-0002-0327-4619ДзерановаЛариса КонстантиновнаDzeranovaLarisa K.

д.м.н, главный научный сотрудник

MD, PhD

dzeranovalk@yandex.ruhttps://orcid.org/0000-0002-8175-7886ДедовИван ИвановичDedovIvan I.

Д.м.н., профессор, академик РАН, Президент ФГБУ "НМИЦ эндокринологии" МЗ РФ

MD, PhD, Professor, Academician of the RAS, President of Endocrinology Research Centre

dedov@endocrincentr.ruhttps://orcid.org/0000-0002-9783-3599МамедоваЕлизавета ОктаевнаMamedovaElizaveta O.

к.м.н., старший научный сотрудник отделения нейроэндокринологии и остеопатий

MD, PhD

lilybet@mail.ruhttps://orcid.org/0000-0001-8303-3825НиканкинаЛариса ВячеславовнаNikankinaLarisa V.

К.м.н., и.о. заведующей клинико-диагностической лабораторией

PhD, Acting Head of the Clinical Diagnostic Laboratory

larisanikan@rambler.ruhttps://orcid.org/0000-0001-6539-466XПигароваЕкатерина АлександровнаPigarovaEkaterina A.

д.м.н., ведущий научный сотрудник отделения нейроэндокринологии и остеопатий

MD, PhD

kpigarova@gmail.comhttps://orcid.org/0000-0001-7965-9454ТарбаеваНаталья ВикторовнаTarbaevaNatalya V.

к.м.н., врач-рентгенолог

MD, PhD

ntarbaeva@inbox.ruhttps://orcid.org/0000-0003-1966-0159ЧерноваТатьяна ОлеговнаChernovaTatiana O.

К.м.н., в.н.с. отделения лучевой диагностики

MD, PhD, Leading Research Scientist, Department of Radiology and X-ray diagnostics

tatcher2@yandex.ruhttps://orcid.org/0000-0002-7856-1567БеловаКсения ЮрьевнаBelovaKsenia Y.

д.м.н., заведующая областным лечебно-диагностическим центром остеопороза и остеоартроза

MD, PhD

ksbelova@mail.ruhttps://orcid.org/0000-0001-9007-4123БирюковаЕлена ВалерьевнаBiryukovaElena V.

Д.м.н., профессор, кафедра эндокринологии и диабетологии

MD, PhD, Professor

lena@obsudim.ruhttps://orcid.org/0000-0002-4453-8430ДрапкинаОксана МихайловнаDrapkinaOksana M.

д.м.н., профессор, член-корр. РАН

MD, PhD, Professor

drapkina@bk.ruhttps://orcid.org/0000-0002-3135-9003ДревальАлександр ВасильевичDrevalAleksandr V.

д.м.н., профессор, заведующий кафедрой клинической эндокринологии ФУВ МОНИКИ, руководитель отделения терапевтической эндокринологии 

MD, PhD, Professor

dreval@diabet.ruhttps://orcid.org/0000-0001-7167-2187ЕршоваОльга БорисовнаErshovaOlga B.

д.м.н., профессор, профессор кафедры терапии имени профессора Е.Н. Дормидонтова

MD, PhD, Professor

yarosteoporosis@list.ruhttps://orcid.org/0000-0002-6736-9772ЗагороднийНиколай ВасильевичZagorodniyNikolay V.

Д.м.н, профессор, руководитель Клиники эндопротезирования на базе ЦИТО им. Н.Н. Приорова, заведующий кафедрой травматологии и ортопедии РУДН, заведующий кафедрой травматологии и ортопедии ФФМ МГУ, главный ортопед-травматолог г. Москвы

MD, PhD, Professor

Zagorodniy51@mail.ruhttps://orcid.org/0000-0002-7876-5105КрюковаИрина ВикторовнаKryukovaIrina V.

К.м.н., ассистент кафедры эндокринологии факультета усовершенствования врачей

MD, PhD, Assistant Professor

kiv200877@yandex.ruhttps://orcid.org/0000-0002-0143-0614ЛеснякОльга МихайловнаLesnyakOlga M.

д.м.н., проф.

MD, PhD, Professor

olga.m.lesnyak@yandex.ruМарченковаЛариса АлександровнаMarchenkovaLarisa A.

к.м.н., ведущий научный сотрудник

MD, PhD

marchenkovaLA@rncmrik.comhttps://orcid.org/0000-0001-6759-8367НикитинскаяОксана АнатольевнаNikitinskayaOksana A.

кандидат медицинских наук, старший научный сотрудник лаборатории остеопороза 

Senior Researcher, Osteoporosis laboratory

nikitinskayaox@yandex.ruhttps://orcid.org/0000-0002-2726-8758РодионоваСветлана СеменовнаRodionovaSvetlana S.

д.м.н., проф., руководитель научно-клинического центра остеопороза 

MD, PhD, Professor

rod06@inbox.ruhttps://orcid.org/0000-0002-1763-0725СкрипниковаИрина АнатольевнаSkripnikovaIrina A.

Д.м.н, руководитель отдела профилактики остеопороза, профессор кафедры клинической и социальной гериатрии ФПКМР РУДН

MD, PhD, Professor

ISkripnikova@gnicpm.ruhttps://orcid.org/0000-0003-4739-4302ТоропцоваНаталья ВладимировнаToroptsovaNatalia V.

доктор медицинских наук

MD, PhD

torop@irramn.ruhttps://orcid.org/0000-0002-8694-3880ФарбаЛеонид ЯковлевичFarbaLeonid Ya.

Врач-хирург травматологического отделения

MD

farbasurg@mail.ruhttps://orcid.org/0000-0003-2864-066XЮреневаСветлана ВладимировнаYurenevaSvetlana V.

д.м.н., ведущий научный сотрудник

MD, PhD

syureneva@gmail.comhttps://orcid.org/0000-0002-7430-1207ЯкушевскаяОксана ВладимировнаYakushevskayaOksana V.

К.м.н., научный сотрудник отделения гинекологической эндокринологии

MD, PhD

Ykushox83@mail.ruhttps://orcid.org/0000-0001-7891-6850ДудинскаяЕкатерина НаильевнаDudinskayaEkaterina N.

к.м.н.

MD, PhD

katharina.gin@gmail.comhttps://orcid.org/0000-0002-4193-688XТкачеваОльга НиколаевнаTkachevaOlga N.

д.м.н., профессор

MD, PhD, professor

tkacheva@rambler.ruhttps://orcid.org/0000-0002-3129-4326KanisJohn AKanisJohn A

Emeritus Professor in Human Metabolism, and Director of the Centre for Metabolic Bone Diseases (Formerly WHO Collaborating Centre), University of Sheffield, UK and Professorial Fellow at the Catholic University of Australia (Melbourne).

Emeritus Professor in Human Metabolism, and Director of the Centre for Metabolic Bone Diseases (Formerly WHO Collaborating Centre), University of Sheffield, UK and Professorial Fellow at the Catholic University of Australia (Melbourne).

w.j.pontefract@sheffield.ac.ukПетряйкинАлексей ВладимировичPetryaykinAlexei V

к.м.н., доцент, старший научный сотрудник

MD, PhD

a.petraikin@npcmr.ruИлюхинаОльга БорисовнаIlyukhinaOlga B

главный внештатный эндокринолог Оренбургской области

MD

olga-andrey1998@mail.ruФГБУ «НМИЦ эндокринологии» Минздрава РоссииРоссияThe National Medical Research Center for EndocrinologyRussian FederationФГБУ "НМИЦ эндокринологии" Минздрава РоссииThe National Medical Research Center for EndocrinologyФГБУ «НМИЦ эндокринологии», Минздрава РФРоссияEndocrinology Research CentreRussian FederationФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава РоссииРоссияEndocrinology Research CentreRussian FederationФГБУ «Нaциональный медицинский исследовательский центр эндокринологии» Минздрава РоссииРоссияEndocrinology Research CentreRussian FederationФГБУ "Национальный медицинский исследовательский центр эндокринологии" МЗ РФ; Первый Московский государственный медицинский университет имени И.М.Сеченова (Сеченовский университет)РоссияEndocrinology Research Centre; I.M.Sechenov First Moscow State Medical Unoversity (Sechenov University)Russian FederationФГБУ "Национальный медицинский исследовательский центр эндокринологии" МЗ РФРоссияEndocrinology Research CentreRussian FederationФГБОУ ВО «Ярославский государственный медицинский университет» Министерства здравоохраненияРоссияYaroslavl State Medical UniversityRussian FederationФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова»РоссияMoscow State University of Medicine and Dentistry named after A.I. EvdokimovRussian FederationФГБУ «Государственный научно-исследовательский центр профилактической медицины» Минздрава РоссииРоссияNational Research Center for Preventive MedicineRussian FederationМосковский областной научно-исследовательский клинический институт (МОНИКИ) им.М.Ф.ВладимирскогоРоссияMoscow Regional Research Clinical InstituteRussian FederationФГБУ «Центральный научно-исследовательский институт травматологии и ортопедии им. Н.Н. Приорова»; ФГАОУ ВО «Российский университет дружбы народов»РоссияCentral Research Institute of Traumatology and Orthopedics named after N.N. Priorova; Peoples Friendship University of RussiaRussian FederationМосковский областной научно-исследовательский клинический институт им. М.Ф. ВладимирскогоРоссияM.F. Vladimirskiy Moscow Regional Research and Clinical InstituteRussian FederationФГБОУ ВО «Северо-Западный государственный медицинский университет имени И.И. Мечникова» Минздрава РоссииРоссияNorth-Western State Medical University named after I.I. MechnikovRussian FederationФГБУ «Национальный медицинский исследовательский центр реабилитации и курортологии» Минздрава РоссииРоссияRussian scientific center of medical rehabilitation and balneologyRussian FederationФГБНУ Научно-исследовательский институт ревматологии имени В.А. НасоновойРоссияResearch Institute of Rheumatogy named after V.A. NasonovaRussian FederationФГБУ Центральный научно-исследовательский институт травматологии и ортопедии имени Н.Н. Приорова Минздрава РоссииРоссияCentral Institute of Traumatology and Orthopaedics named after N.N. PriorovRussian FederationФГБУ «Государственный научно-исследовательский центр профилактической медицины» Минздрава РоссииРоссияNational Research Center for Preventive Medicine; Peoples Friendship University of RussiaRussian FederationГБУЗ «Городская клиническая больница №13» Департамента здравоохранения МосквыРоссияMunicipal Clinical Hospital №13Russian FederationФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Минздрава РоссииРоссияResearch Center for Obstetrics, Gynecology and PerinatologyRussian FederationФГБУ «Научный центр акушерства, гинекологии и перинатологии им. В.И. Кулакова» Минздрава РоссииРоссияResearch Center for Obstetrics, Gynecology and PerinatologyRussian FederationРоссийский национальный исследовательский медицинский университет им. Н.И. ПироговаРоссияPirogov Russian National Research Medical UniversityRussian FederationUniversity of Sheffield, UK Catholic University of Australia (Melbourne).University of Sheffield, UK Catholic University of Australia (Melbourne).ГБУЗ города Москвы «Научно-практический клинический центр диагностики и телемедицинских технологий Департамента здравоохранения города Москвы».Scientific and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Department of Health.ГАУЗ Оренбургская областная клиническая больница №2Orenburg Regional Clinical Hospital №2202004032021232421Copyright © Гребенникова Т.А., Белая Ж.Е., Мельниченко Г.А., Рожинская Л.Я., Цориев Т.Т., Дзеранова Л.К., Дедов И.И., Мамедова Е.О., Никанкина Л.В., Пигарова Е.А., Тарбаева Н.В., Чернова Т.О., Белова К.Ю., Бирюкова Е.В., Драпкина О.М., Древаль А.В., Ершова О.Б., Загородний Н.В., Крюкова И.В., Лесняк О.М., Марченкова Л.А., Никитинская О.А., Родионова С.С., Скрипникова И.А., Торопцова Н.В., Фарба Л.Я., Юренева С.В., Якушевская О.В., Дудинская Е.Н., Ткачева О.Н., Kanis J.A., Петряйкин А.В., Илюхина О.Б., 20212021Гребенникова Т.А., Белая Ж.Е., Мельниченко Г.А., Рожинская Л.Я., Цориев Т.Т., Дзеранова Л.К., Дедов И.И., Мамедова Е.О., Никанкина Л.В., Пигарова Е.А., Тарбаева Н.В., Чернова Т.О., Белова К.Ю., Бирюкова Е.В., Драпкина О.М., Древаль А.В., Ершова О.Б., Загородний Н.В., Крюкова И.В., Лесняк О.М., Марченкова Л.А., Никитинская О.А., Родионова С.С., Скрипникова И.А., Торопцова Н.В., Фарба Л.Я., Юренева С.В., Якушевская О.В., Дудинская Е.Н., Ткачева О.Н., Kanis J.A., Петряйкин А.В., Илюхина О.Б.Grebennikova T.A., Belaya Z.E., Melnichenko G.A., Rozhinskaya L.Y., Tsoriev T.T., Dzeranova L.K., Dedov I.I., Mamedova E.O., Nikankina L.V., Pigarova E.A., Tarbaeva N.V., Chernova T.O., Belova K.Y., Biryukova E.V., Drapkina O.M., Dreval A.V., Ershova O.B., Zagorodniy N.V., Kryukova I.V., Lesnyak O.M., Marchenkova L.A., Nikitinskaya O.A., Rodionova S.S., Skripnikova I.A., Toroptsova N.V., Farba L.Y., Yureneva S.V., Yakushevskaya O.V., Dudinskaya E.N., Tkacheva O.N., Kanis J.A., Petryaykin A.V., Ilyukhina O.B.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.osteo-endojournals.ru/jour/article/view/12373Представлено краткое изложение проекта федеральных клинических рекомендаций по остеопорозу, разработанных членами Российской ассоциации эндокринологов, Российской ассоциации по остеопорозу, Ассоциации ревматологов России, Ассоциации травматологов-ортопедов России, Российской ассоциации по менопаузе и Российской ассоциации геронтологов и гериатров. Рекомендации разработаны с позиций доказательной медицины, в соответствии с требованиями к составлению клинических рекомендаций Минздрава России, опубликованными в 2019 г. Значительное место в изложении отведено скринингу первичного остеопороза у взрослых, дифференциальной диагностике с другими метаболическими заболеваниями скелета, современным методам диагностики остеопороза, принципам назначения патогенетического лечения, особенности последовательной и комбинированной терапии, профилактики заболевания и реабилитации.Клинические рекомендации полезны будут как врачам общей практики и терапевтам, так и узким специалистам, прежде всего эндокринологам, ревматологам, травматологам-ортопедам, нефрологам, акушерам-гинекологам и неврологам, так как остеопороз является мультифакториальным и мультидисциплинарным заболеванием.A summary of the draft federal clinical guidelines on osteoporosis developed by members of the Russian Association of Endocrinologists, the Russian Association for Osteoporosis, the Association of Rheumatologists of Russia, the Association of Traumatologists and Orthopedists of Russia, the Russian Association for Menopause and the Russian Association of Gerontologists and Geriatrics is presented. The recommendations were developed from the perspective of evidence-based medicine, in accordance with the requirements for compiling clinical recommendations of the Ministry of Health of Russia published in 2019. A significant place is given to screening of primary osteoporosis in adults, differential diagnosis with other metabolic diseases of the skeleton, modern methods of diagnosing osteoporosis, principles of prescribing pathogenetic treatment, features of sequential and combination therapy, disease prevention and rehabilitation.Clinical recommendations will be useful both to general practitioners and physicians, as well as to narrow specialists, primarily endocrinologists, rheumatologists, orthopedic traumatologists, nephrologists, obstetrician-gynecologists and neurologists, since osteoporosis is a multifactorial and multidisciplinary disease.остеопорозпереломFRAXтрабекулярный костный индексденситометриятерипаратидденосумаббисфосфонатыкальцийвитамин DosteoporosisfractureFRAXtrabecular bone scoredensitometryteriparatidedenosumabbisphosphonatescalciumvitamin DReferencesKanis JA, on behalf of the WHO Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaboraiting Centre, University of Sheffield, UK, 2008Kanis JA, on behalf of the WHO Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaboraiting Centre, University of Sheffield, UK, 2008Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993 Jun;94(6):646-50. DOI: 10.1016/0002-9343(93)90218-eConsensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993 Jun;94(6):646-50. DOI: 10.1016/0002-9343(93)90218-eМельниченко Г.А., Белая Ж.Е., Рожинская Л.Я., Торопцова Н.В., Алексеева Л.И., Бирюкова Е.В., Гребенникова Т.А., Дзеранова Л.К., Древаль А.В., Загородний Н.В., Ильин А.В., Крюкова И.В., Лесняк О.М, Мамедова Е.О., Никитинская О.А., Пигарова Е.А., Родионова С.С., Скрипникова И.А., Тарбаева Н.В., Фарба Л.Я., Цориев Т.Т., Чернова Т.О., Юренева С.В., Якушевская О.В., Дедов И.И.. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. Проблемы Эндокринологии, 2017, Том 63, № 6, стр. 392-426Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я., Торопцова Н.В., Алексеева Л.И., Бирюкова Е.В., Гребенникова Т.А., Дзеранова Л.К., Древаль А.В., Загородний Н.В., Ильин А.В., Крюкова И.В., Лесняк О.М, Мамедова Е.О., Никитинская О.А., Пигарова Е.А., Родионова С.С., Скрипникова И.А., Тарбаева Н.В., Фарба Л.Я., Цориев Т.Т., Чернова Т.О., Юренева С.В., Якушевская О.В., Дедов И.И.. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. Проблемы Эндокринологии, 2017, Том 63, № 6, стр. 392-426Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, Miller PD, Narula HS, Pessah-Pollack R, Tangpricha V,Wimalawansa SJ, Watts NB: American association of clinical endocrinologists and American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis -2016. Endocr Pract. 2016 Sep 2;22(Suppl 4):1-42.Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, Miller PD, Narula HS, Pessah-Pollack R, Tangpricha V,Wimalawansa SJ, Watts NB: American association of clinical endocrinologists and American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis -2016. Endocr Pract. 2016 Sep 2;22(Suppl 4):1-42.Kanis JA, Cooper C, Rizzoli R, Reginster JY; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF).European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019 Jan;30(1):3-44. doi: 10.1007/s00198-018-4704-5Kanis JA, Cooper C, Rizzoli R, Reginster JY; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF).European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019 Jan;30(1):3-44. doi: 10.1007/s00198-018-4704-5Raman-Wilms L. Book Review: Guidelines for Preclinical Evaluation and Clinical Trials in Osteoporosis. Annals of Pharmacotherapy. 1999;33(12):1377-1378. doi:10.1177/106002809903301207.Raman-Wilms L. Book Review: Guidelines for Preclinical Evaluation and Clinical Trials in Osteoporosis. Annals of Pharmacotherapy. 1999;33(12):1377-1378. doi:10.1177/106002809903301207.American Association of Orthopedic Surgeon Position Statement, 1159, December 2009American Association of Orthopedic Surgeon Position Statement, 1159, December 2009Shepstone L, Lenaghan E, Cooper C, et al. SCOOP Study Team. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Lancet. 2018 Feb 24;391(10122):741-747. doi: 10.1016/S0140-6736(17)32640-5.Shepstone L, Lenaghan E, Cooper C, et al. SCOOP Study Team. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Lancet. 2018 Feb 24;391(10122):741-747. doi: 10.1016/S0140-6736(17)32640-5.Turner DA, Khioe RFS, Shepstone L, et al. SCOOP Study Team. The Cost-Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study. J Bone Miner Res. 2018 May;33(5):845-851. doi: 10.1002/jbmr.3381.Turner DA, Khioe RFS, Shepstone L, et al. SCOOP Study Team. The Cost-Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study. J Bone Miner Res. 2018 May;33(5):845-851. doi: 10.1002/jbmr.3381.Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, et al. Risk of new vertebral fracture in the year following a fracture. JAMA. 2001;285:320-323Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, et al. Risk of new vertebral fracture in the year following a fracture. JAMA. 2001;285:320-323Gehlbach S, Saag KG, Adachi JD, Hooven FH, Flahive J, Boonen S, et al. Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women. J Bone Miner Res. 2012;27:645-653,Gehlbach S, Saag KG, Adachi JD, Hooven FH, Flahive J, Boonen S, et al. Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women. J Bone Miner Res. 2012;27:645-653,Edwards BJ, Bunta AD, Simonelli C, Bolander M, Fitzpatrick LA. Prior fractures are common in patients with subsequent hip fractures. Clin Orthop Relat Res. 2007;461:226-230Edwards BJ, Bunta AD, Simonelli C, Bolander M, Fitzpatrick LA. Prior fractures are common in patients with subsequent hip fractures. Clin Orthop Relat Res. 2007;461:226-230Ross P. Pre-Existing Fractures and Bone Mass Predict Vertebral Fracture Incidence in Women. Annals of Internal Medicine. 1991;114(11):919. doi:10.7326/0003-4819-114-11-919.Ross P. Pre-Existing Fractures and Bone Mass Predict Vertebral Fracture Incidence in Women. Annals of Internal Medicine. 1991;114(11):919. doi:10.7326/0003-4819-114-11-919.Kanis J, Melton L, Christiansen C, Johnston C, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 2009;9(8):1137-1141. doi:10.1002/jbmr.5650090802.Kanis J, Melton L, Christiansen C, Johnston C, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 2009;9(8):1137-1141. doi:10.1002/jbmr.5650090802.Yamamoto M, Yamaguchi T, Yamauchi M, Kaji H, Sugimoto T. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res. 2009 Apr;24(4):702-9. doi: 10.1359/jbmr.081207.Yamamoto M, Yamaguchi T, Yamauchi M, Kaji H, Sugimoto T. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res. 2009 Apr;24(4):702-9. doi: 10.1359/jbmr.081207.Dede AD, Tournis S, Dontas I, Trovas G. Type 2 diabetes mellitus and fracture risk. Metabolism. 2014 Dec;63(12):1480-90. doi: 10.1016/j.metabol.2014.09.002.Dede AD, Tournis S, Dontas I, Trovas G. Type 2 diabetes mellitus and fracture risk. Metabolism. 2014 Dec;63(12):1480-90. doi: 10.1016/j.metabol.2014.09.002.Schousboe J, Ensrud K, Nyman J, Kane R, Melton L. Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy. Osteoporosis International. 2005;16(12):1883-1893. doi:10.1007/s00198-005-1956-7Schousboe J, Ensrud K, Nyman J, Kane R, Melton L. Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy. Osteoporosis International. 2005;16(12):1883-1893. doi:10.1007/s00198-005-1956-7Lesnyak O, Ershova O, Belova K et al. Epidemiology of fracture in the Russian Federation and the development of a FRAX model. Arch Osteoporos. 2012;7(1-2):67-73. doi:10.1007/s11657-012-0082-3.Lesnyak O, Ershova O, Belova K et al. Epidemiology of fracture in the Russian Federation and the development of a FRAX model. Arch Osteoporos. 2012;7(1-2):67-73. doi:10.1007/s11657-012-0082-3.Kanis JA, Harvey NC, Cooper C et al. A systematic review of intervention thresholds based on FRAX: A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos. 2016 Dec;11(1):25. doi: 10.1007/s11657-016-0278-zKanis JA, Harvey NC, Cooper C et al. A systematic review of intervention thresholds based on FRAX: A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos. 2016 Dec;11(1):25. doi: 10.1007/s11657-016-0278-zCosman F, de Beur S, LeBoff M, de Beur SJ, Tanner B Clinician’s Guide to Prevention and Treatment of Osteoporosis. National Osteoporosis Foundation. 1150 17th St., NW, Suite 850, Washington, DC 20036, Release Date: April 1, 2014Cosman F, de Beur S, LeBoff M, de Beur SJ, Tanner B Clinician’s Guide to Prevention and Treatment of Osteoporosis. National Osteoporosis Foundation. 1150 17th St., NW, Suite 850, Washington, DC 20036, Release Date: April 1, 2014Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A; National Osteoporosis Guideline Group. Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int. 2008 Oct;19(10):1395-408. doi: 10.1007/s00198-008-0712-1Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A; National Osteoporosis Guideline Group. Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int. 2008 Oct;19(10):1395-408. doi: 10.1007/s00198-008-0712-1Kanis J, Johnell O, De Laet C, Jonsson B, Oden A, Ogelsby A. International Variations in Hip Fracture Probabilities: Implications for Risk Assessment. J Bone Miner Res. 2002;17(7):1237-1244. doi:10.1359/jbmr.2002.17.7.1237.Kanis J, Johnell O, De Laet C, Jonsson B, Oden A, Ogelsby A. International Variations in Hip Fracture Probabilities: Implications for Risk Assessment. J Bone Miner Res. 2002;17(7):1237-1244. doi:10.1359/jbmr.2002.17.7.1237.De Laet C, Van Hout B, Burger H, Weel A, Hofman A, Pols H. Hip Fracture Prediction in Elderly Men and Women: Validation in the Rotterdam Study. J Bone Miner Res. 2009;13(10):1587-1593. doi:10.1359/jbmr.1998.13.10.1587.De Laet C, Van Hout B, Burger H, Weel A, Hofman A, Pols H. Hip Fracture Prediction in Elderly Men and Women: Validation in the Rotterdam Study. J Bone Miner Res. 2009;13(10):1587-1593. doi:10.1359/jbmr.1998.13.10.1587.Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int. 1997;7(4):390-406. DOI: 10.1007/bf01623782Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int. 1997;7(4):390-406. DOI: 10.1007/bf01623782Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J-Y, on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013 Jan;24(1):23-57. doi: 10.1007/s00198-012-2074-y.Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J-Y, on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013 Jan;24(1):23-57. doi: 10.1007/s00198-012-2074-y.Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgström F, Cooper C, Diez Perez A, Eastell R, Hofbauer L, Kanis JA, Langdahl BL, Lesnyak O, Lorenc R, McCloskey E, Messina OD, Napoli N, Obermayer-Pietsch B, Ralston SH, Sambrook PN, Silverman S, Sosa M, Stepan J, Suppan G, Wahl DA, Compston JE for the Joint IOF-ECTS GIO Guidelines Working Group. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. 2012 Sep;23(9):2257-76. doi: 10.1007/s00198-012-1958-1Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgström F, Cooper C, Diez Perez A, Eastell R, Hofbauer L, Kanis JA, Langdahl BL, Lesnyak O, Lorenc R, McCloskey E, Messina OD, Napoli N, Obermayer-Pietsch B, Ralston SH, Sambrook PN, Silverman S, Sosa M, Stepan J, Suppan G, Wahl DA, Compston JE for the Joint IOF-ECTS GIO Guidelines Working Group. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. 2012 Sep;23(9):2257-76. doi: 10.1007/s00198-012-1958-1Алексеева ЛИ, Баранова ИА, Белова КЮ, Ершова ОБ, Зазерская ИЕ, Зоткин ЕГ, Лесняк ОМ, Никитинская ОА, Рожинская ЛЯ, Скрипникова ИА, Смирнов АВ, Щеплягина ЛА.: Клинические рекомендации по профилактике и ведению больных с остеопорозом. Литера;2012:23.Алексеева ЛИ, Баранова ИА, Белова КЮ, Ершова ОБ, Зазерская ИЕ, Зоткин ЕГ, Лесняк ОМ, Никитинская ОА, Рожинская ЛЯ, Скрипникова ИА, Смирнов АВ, Щеплягина ЛА.: Клинические рекомендации по профилактике и ведению больных с остеопорозом. Литера;2012:23.National Osteoporosis Foundation (NOF) and International Society for Clinical Densitometry (ISCD). Recommendations to DXA Manufacturers for FRAX® Implementation. Available http://www.nof.org/files/nof/public/content/resource/862/files/392.pdf. Accessed January 28, 2013National Osteoporosis Foundation (NOF) and International Society for Clinical Densitometry (ISCD). Recommendations to DXA Manufacturers for FRAX® Implementation. Available http://www.nof.org/files/nof/public/content/resource/862/files/392.pdf. Accessed January 28, 2013Kanis J, Johnell O, Oden A, Johansson H, McCloskey E. FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporosis International. 2008;19(4):385-397. doi:10.1007/s00198-007-0543-5Kanis J, Johnell O, Oden A, Johansson H, McCloskey E. FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporosis International. 2008;19(4):385-397. doi:10.1007/s00198-007-0543-5Kanis JA, Johansson H, Odén A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 2011: 22:809–816Kanis JA, Johansson H, Odén A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 2011: 22:809–816Kanis JA, Johansson H, Oden A et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004 Jun;19(6):893-9. DOI: 10.1359/JBMR.040134Kanis JA, Johansson H, Oden A et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004 Jun;19(6):893-9. DOI: 10.1359/JBMR.040134Van Staa TP, Leufkens HGM, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002 Oct;13(10):777-87.Van Staa TP, Leufkens HGM, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002 Oct;13(10):777-87.Ferrari SL, Abrahamsen B, Napoli N, et al; Bone and Diabetes Working Group of IOF. Diagnosis and management of bone fragility in diabetes: an emerging challenge.Osteoporos Int. 2018 Dec;29(12):2585-2596. doi: 10.1007/s00198-018-4650-2Ferrari SL, Abrahamsen B, Napoli N, et al; Bone and Diabetes Working Group of IOF. Diagnosis and management of bone fragility in diabetes: an emerging challenge.Osteoporos Int. 2018 Dec;29(12):2585-2596. doi: 10.1007/s00198-018-4650-2Leslie WD, Johansson H, McCloskey EV, Harvey NC, Kanis JA, Hans D. Comparison of Methods for Improving Fracture Risk Assessment in Diabetes: The Manitoba BMD Registry. J Bone Miner Res. 2018 Nov;33(11):1923-1930. doi: 10.1002/jbmr.3538Leslie WD, Johansson H, McCloskey EV, Harvey NC, Kanis JA, Hans D. Comparison of Methods for Improving Fracture Risk Assessment in Diabetes: The Manitoba BMD Registry. J Bone Miner Res. 2018 Nov;33(11):1923-1930. doi: 10.1002/jbmr.3538Baleanu F, Bergmann P, Hambye AS, Dekelver C, Iconaru L, Cappelle SI, Moreau M, Paesmans M, Karmali R, Body JJ. Assessment of bone quality with trabecular bone score in type 2 diabetes mellitus: A study from the FRISBEE cohort. Int J Clin Pract. 2019 Mar 26:e13347. doi: 10.1111/ijcp.13347Baleanu F, Bergmann P, Hambye AS, Dekelver C, Iconaru L, Cappelle SI, Moreau M, Paesmans M, Karmali R, Body JJ. Assessment of bone quality with trabecular bone score in type 2 diabetes mellitus: A study from the FRISBEE cohort. Int J Clin Pract. 2019 Mar 26:e13347. doi: 10.1111/ijcp.13347Johansson H, Odén A, Johnell O, Jonsson B, de Laet C, Oglesby A, McCloskey EV, Kayan K, Jalava T, Kanis JA (2004) Optimization of BMD measurements to identify high risk groups for treatment—a test analysis. J Bone Miner Res 19:906–913Johansson H, Odén A, Johnell O, Jonsson B, de Laet C, Oglesby A, McCloskey EV, Kayan K, Jalava T, Kanis JA (2004) Optimization of BMD measurements to identify high risk groups for treatment—a test analysis. J Bone Miner Res 19:906–913Tosteson AN, Melton LJ, 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437–447Tosteson AN, Melton LJ, 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437–447Leslie WD, Morin S, Lix LM, Johansson H, Odén A, McCloskey E, Kanis JA (2012) Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporos Int 23:75–85Leslie WD, Morin S, Lix LM, Johansson H, Odén A, McCloskey E, Kanis JA (2012) Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporos Int 23:75–85Leslie WD, Majumdar SR, Lix LM, Johansson H, Odén A, McCloskey E, Kanis JA (2012) High fracture probability with FRAX usually indicates densitometric osteoporosis: implications for clinical practice. Osteoporos Int 23:391–397Leslie WD, Majumdar SR, Lix LM, Johansson H, Odén A, McCloskey E, Kanis JA (2012) High fracture probability with FRAX usually indicates densitometric osteoporosis: implications for clinical practice. Osteoporos Int 23:391–397Kanis JA, Odén A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 18:1033–1046.Kanis JA, Odén A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 18:1033–1046.Kyriakos G, Vidal-Casariego A, Fernandez-Martinez MN et al. Impact of the NOGG and NOF guidelines on the indication of bone mineral density in routine clinical practice. J Clin Densitom. 2015 Oct-Dec;18(4):533-8. doi: 10.1016/j.jocd.2015.08.001.Kyriakos G, Vidal-Casariego A, Fernandez-Martinez MN et al. Impact of the NOGG and NOF guidelines on the indication of bone mineral density in routine clinical practice. J Clin Densitom. 2015 Oct-Dec;18(4):533-8. doi: 10.1016/j.jocd.2015.08.001.ISCD positions. Journal of Clinical Densitometry. 2004;7(1).ISCD positions. Journal of Clinical Densitometry. 2004;7(1).Official Positions of the International Society for Clinical Densitometry. Copyright ISCD, October 2007.Official Positions of the International Society for Clinical Densitometry. Copyright ISCD, October 2007.Shepherd JA, Blake GM . T-scores and Z-scores. J Clin Densitom. 2007 Oct-Dec;10(4):349-50. DOI: 10.1016/j.jocd.2007.08.006Shepherd JA, Blake GM . T-scores and Z-scores. J Clin Densitom. 2007 Oct-Dec;10(4):349-50. DOI: 10.1016/j.jocd.2007.08.006Watts NB, Leslie WD, Foldes AJ, Miller PD. International Society for Clinical Densitometry Position Development Conference: Task Force on Normative Databases. J Clin Densitom. 2013 Oct-Dec;16(4):472-81. doi: 10.1016/j.jocd.2013.08.001.Watts NB, Leslie WD, Foldes AJ, Miller PD. International Society for Clinical Densitometry Position Development Conference: Task Force on Normative Databases. J Clin Densitom. 2013 Oct-Dec;16(4):472-81. doi: 10.1016/j.jocd.2013.08.001.Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organization, Geneva. World Health Organ Tech Rep Ser. 1994;843:1-129.Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organization, Geneva. World Health Organ Tech Rep Ser. 1994;843:1-129.Kelly TL. Bone mineral density reference databases for American men and women. J Bone Miner Res 1990, 5(Suppl 2):S249.Kelly TL. Bone mineral density reference databases for American men and women. J Bone Miner Res 1990, 5(Suppl 2):S249.Hanson J. Standardization of femur BMD. J Bone Miner Res 1997, 12:1316e1317.Hanson J. Standardization of femur BMD. J Bone Miner Res 1997, 12:1316e1317.Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd, Khaltaev N. A reference standard for the description of osteoporosis. Bone. 2008 Mar;42(3):467-75. doi: 10.1016/j.bone.2007.11.001.Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd, Khaltaev N. A reference standard for the description of osteoporosis. Bone. 2008 Mar;42(3):467-75. doi: 10.1016/j.bone.2007.11.001.Melton LJ. Chrischilles EA, Cooper C, Lane AW, Riggs BL. How many women have osteoporosis. J Bone Miner Res 1993:7: 1005-1010.Melton LJ. Chrischilles EA, Cooper C, Lane AW, Riggs BL. How many women have osteoporosis. J Bone Miner Res 1993:7: 1005-1010.McCloskey EV, Odén A, Harvey NC, et al. A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and its Relationship to FRAX. J Bone Miner Res. 2016 May;31(5):940-8. doi: 10.1002/jbmr.2734.McCloskey EV, Odén A, Harvey NC, et al. A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and its Relationship to FRAX. J Bone Miner Res. 2016 May;31(5):940-8. doi: 10.1002/jbmr.2734.Gallagher JC, Sai AJ. Bone: Is screening for secondary causes of osteoporosis worthwhile? Nat Rev Endocrinol. 2010;6:360-362Gallagher JC, Sai AJ. Bone: Is screening for secondary causes of osteoporosis worthwhile? Nat Rev Endocrinol. 2010;6:360-362Barzel US. Recommended testing in patients with low bone density. J Clin Endocrinol Metab. 2003;88:1404- 1405Barzel US. Recommended testing in patients with low bone density. J Clin Endocrinol Metab. 2003;88:1404- 1405Tannenbaum C, Clark J, Schwartzman K, Wallenstein S, Lapinski R, Meier D, et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab. 2002;87: 4431-4437Tannenbaum C, Clark J, Schwartzman K, Wallenstein S, Lapinski R, Meier D, et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab. 2002;87: 4431-4437Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348:1535–1541.Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348:1535–1541.Cummings SR, Black DM, Thompson DE et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998; 280:2077–2082. doi:10.1001/jama.280.24.2077Cummings SR, Black DM, Thompson DE et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998; 280:2077–2082. doi:10.1001/jama.280.24.2077Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000 Aug 31;343(9):604-10. DOI: 10.1056/NEJM200008313430902Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000 Aug 31;343(9):604-10. DOI: 10.1056/NEJM200008313430902Saag K, Emkey R, Schnitzer T et al. Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Obstetrical & Gynecological Survey. 1999;54(1):39-40. doi:10.1097/00006254-199901000-00021Saag K, Emkey R, Schnitzer T et al. Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Obstetrical & Gynecological Survey. 1999;54(1):39-40. doi:10.1097/00006254-199901000-00021McClung MR, Geusens P , Miller PD , et al.Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.N Engl J Med. 2001; 344: 333-340McClung MR, Geusens P , Miller PD , et al.Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.N Engl J Med. 2001; 344: 333-340Boonen S, Orwoll E, Wenderoth D, Stoner K, Eusebio R, Delmas P. Once-Weekly Risedronate in Men With Osteoporosis: Results of a 2-Year, Placebo-Controlled, Double-Blind, Multicenter Study. Journal of Bone and Mineral Research. 2009;24(4):719-725. doi:10.1359/jbmr.081214Boonen S, Orwoll E, Wenderoth D, Stoner K, Eusebio R, Delmas P. Once-Weekly Risedronate in Men With Osteoporosis: Results of a 2-Year, Placebo-Controlled, Double-Blind, Multicenter Study. Journal of Bone and Mineral Research. 2009;24(4):719-725. doi:10.1359/jbmr.081214Eastell R, Devogelaer J, Peel N et al. Prevention of Bone Loss with Risedronate in Glucocorticoid-Treated Rheumatoid Arthritis Patients. Osteoporosis International. 2000;11(4):331-337. doi:10.1007/s001980070122Eastell R, Devogelaer J, Peel N et al. Prevention of Bone Loss with Risedronate in Glucocorticoid-Treated Rheumatoid Arthritis Patients. Osteoporosis International. 2000;11(4):331-337. doi:10.1007/s001980070122Chesnut CH 3rd, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004 Aug;19(8):1241-9. Epub 2004 Mar 29.Chesnut CH 3rd, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004 Aug;19(8):1241-9. Epub 2004 Mar 29.Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendler DL, Bolognese MA, Mairon N, Cooper C. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study J Bone Miner Res. 2005 Aug;20(8):1315-22. Epub 2005 Mar 14.Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendler DL, Bolognese MA, Mairon N, Cooper C. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study J Bone Miner Res. 2005 Aug;20(8):1315-22. Epub 2005 Mar 14.Recker RR, Ste-Marie LG, Langdahl B, Czerwinski E, Bonvoisin B, Masanauskaite D, Rowell L, Felsenberg D. Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study. Bone. 2010 Mar;46(3):660-5. doi: 10.1016/j.bone.2009.11.004. Epub 2009 Nov 10.Recker RR, Ste-Marie LG, Langdahl B, Czerwinski E, Bonvoisin B, Masanauskaite D, Rowell L, Felsenberg D. Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study. Bone. 2010 Mar;46(3):660-5. doi: 10.1016/j.bone.2009.11.004. Epub 2009 Nov 10.Harris S, Blumentals W, Miller P. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Current Medical Research and Opinion. 2007;24(1):237-245. doi:10.1185/030079908x253717Harris S, Blumentals W, Miller P. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Current Medical Research and Opinion. 2007;24(1):237-245. doi:10.1185/030079908x253717Black D, Delmas P, Eastell R et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. N Engl J Med. 2007 May 3;356(18):1809-22 DOI: 10.1056/NEJMoa067312Black D, Delmas P, Eastell R et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. N Engl J Med. 2007 May 3;356(18):1809-22 DOI: 10.1056/NEJMoa067312Boonen S, Reginster J, Kaufman J et al. Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis. New England Journal of Medicine. 2012;367(18):1714-1723Boonen S, Reginster J, Kaufman J et al. Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis. New England Journal of Medicine. 2012;367(18):1714-1723Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN; HORIZON investigators. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009 Apr 11;373(9671):1253-63. doi: 10.1016/S0140-6736(09)60250-6Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN; HORIZON investigators. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009 Apr 11;373(9671):1253-63. doi: 10.1016/S0140-6736(09)60250-6Kenneth W. Lyles, Cathleen S. Colón-Emeric, M.H.Sc., Jay S. Magaziner, et al for the HORIZON Recurrent Fracture Trial* Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. N Engl J Med. 2007;357:1799-1809Kenneth W. Lyles, Cathleen S. Colón-Emeric, M.H.Sc., Jay S. Magaziner, et al for the HORIZON Recurrent Fracture Trial* Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. N Engl J Med. 2007;357:1799-1809McClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou C. Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass. Obstetrics & Gynecology. 2009;114(5):999-1007. doi:10.1097/aog.0b013e3181bdce0aMcClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou C. Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass. Obstetrics & Gynecology. 2009;114(5):999-1007. doi:10.1097/aog.0b013e3181bdce0aReid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wong S, Wiessing KR, Bolland MJ, Bastin S, Gamble GD. Fracture Prevention with Zoledronate in Older Women with Osteopenia. N Engl J Med. 2018 Dec 20;379(25):2407-2416. doi: 10.1056/NEJMoa1808082Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wong S, Wiessing KR, Bolland MJ, Bastin S, Gamble GD. Fracture Prevention with Zoledronate in Older Women with Osteopenia. N Engl J Med. 2018 Dec 20;379(25):2407-2416. doi: 10.1056/NEJMoa1808082Cummings S, Martin J, McClung M et al. Denosumab for Prevention of Fractures in Postmenopausal Women With Osteoporosis. N Engl J Med. 2009 Aug 20;361(8):756-65. doi: 10.1056/NEJMoa0809493. Epub 2009 Aug 11Cummings S, Martin J, McClung M et al. Denosumab for Prevention of Fractures in Postmenopausal Women With Osteoporosis. N Engl J Med. 2009 Aug 20;361(8):756-65. doi: 10.1056/NEJMoa0809493. Epub 2009 Aug 11Langdahl B, Teglbjærg C, Ho P et al. A 24-Month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density: Results From the ADAMO Trial. The Journal of Clinical Endocrinology & Metabolism. 2015;100(4):1335-1342. doi:10.1210/jc.2014-4079Langdahl B, Teglbjærg C, Ho P et al. A 24-Month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density: Results From the ADAMO Trial. The Journal of Clinical Endocrinology & Metabolism. 2015;100(4):1335-1342. doi:10.1210/jc.2014-4079Orwoll E, Teglbjærg C, Langdahl B et al. A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density. The Journal of Clinical Endocrinology & Metabolism. 2012;97(9):3161-3169. doi:10.1210/jc.2012-1569Orwoll E, Teglbjærg C, Langdahl B et al. A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density. The Journal of Clinical Endocrinology & Metabolism. 2012;97(9):3161-3169. doi:10.1210/jc.2012-1569Saag KG, Pannacciulli N, Geusens P, Adachi JD, Messina OD, Morales-Torres J, Emkey R, Butler PW, Yin X, Lems WF. Denosumab vs risedronate in glucocorticoid-induced osteoporosis: final results of a 24-month randomized, double-blind, double-dummy trial. Arthritis Rheumatol. 2019 Feb 28. doi: 10.1002/art.40874Saag KG, Pannacciulli N, Geusens P, Adachi JD, Messina OD, Morales-Torres J, Emkey R, Butler PW, Yin X, Lems WF. Denosumab vs risedronate in glucocorticoid-induced osteoporosis: final results of a 24-month randomized, double-blind, double-dummy trial. Arthritis Rheumatol. 2019 Feb 28. doi: 10.1002/art.40874Gnant M, Pfeiler G, Dubsky P et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. 2015;386(9992):433-443. doi:10.1016/s0140-6736(15)60995-3Gnant M, Pfeiler G, Dubsky P et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. 2015;386(9992):433-443. doi:10.1016/s0140-6736(15)60995-3Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C; DenosumabHALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009 Aug 20;361(8):745-55. doi: 10.1056/NEJMoa0809003. Epub 2009 Aug 11.Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C; DenosumabHALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009 Aug 20;361(8):745-55. doi: 10.1056/NEJMoa0809003. Epub 2009 Aug 11.Amiche MA, Albaum JM, Tadrous M, et al. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network. Osteoporos Int. 2016 Jun;27(6):1989-98. doi: 10.1007/s00198-015-3476-4.Amiche MA, Albaum JM, Tadrous M, et al. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network. Osteoporos Int. 2016 Jun;27(6):1989-98. doi: 10.1007/s00198-015-3476-4.McClung M. Inhibition of RANKL as a treatment for osteoporosis: Preclinical and early clinical studies. Current Osteoporosis Reports. 2006;4(1):28-33. doi:10.1007/s11914-006-0012-7McClung M. Inhibition of RANKL as a treatment for osteoporosis: Preclinical and early clinical studies. Current Osteoporosis Reports. 2006;4(1):28-33. doi:10.1007/s11914-006-0012-7Белая Ж.Е., Рожинская Л.Я. Новые направления в терапии остеопороза – применение моноклональных человеческих антител к RANKL (Деносумаб). Остеопороз и Остеопатии. 2011;2:19-22Белая Ж.Е., Рожинская Л.Я. Новые направления в терапии остеопороза – применение моноклональных человеческих антител к RANKL (Деносумаб). Остеопороз и Остеопатии. 2011;2:19-22Miller P, Bolognese M, Lewiecki E et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. Bone. 2008;43(2):222-229. doi:10.1016/j.bone.2008.04.007Miller P, Bolognese M, Lewiecki E et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. Bone. 2008;43(2):222-229. doi:10.1016/j.bone.2008.04.007Mandema JW1, Zheng J, Libanati C, Perez Ruixo JJ. Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis.J Clin Endocrinol Metab. 2014 Oct;99(10):3746-55. doi: 10.1210/jc .2013-3795. Epub 2014 Jun 10Mandema JW1, Zheng J, Libanati C, Perez Ruixo JJ. Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis.J Clin Endocrinol Metab. 2014 Oct;99(10):3746-55. doi: 10.1210/jc .2013-3795. Epub 2014 Jun 10Brown J, Prince R, Deal C et al. Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial*. Journal of Bone and Mineral Research. 2009;24(1):153-161. doi:10.1359/jbmr.0809010Brown J, Prince R, Deal C et al. Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial*. Journal of Bone and Mineral Research. 2009;24(1):153-161. doi:10.1359/jbmr.0809010Choi NK, Solomon DH, Tsacogianis TN, Landon JE, Song HJ, Kim SC.Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study. J Bone Miner Res. 2016 Oct 13. doi: 10.1002/jbmr.3019.Choi NK, Solomon DH, Tsacogianis TN, Landon JE, Song HJ, Kim SC.Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study. J Bone Miner Res. 2016 Oct 13. doi: 10.1002/jbmr.3019.Kendler D, Roux C, Benhamou C et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2009;25(1):72-81. doi:10.1359/jbmr.090716.Kendler D, Roux C, Benhamou C et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2009;25(1):72-81. doi:10.1359/jbmr.090716.Tsai J, Uihlein A, Burnett-Bowie S et al. Comparative Effects of Teriparatide, Denosumab, and Combination Therapy on Peripheral Compartmental Bone Density, Microarchitecture, and Estimated Strength: the DATA-HRpQCT Study. J Bone Miner Res. 2014;30(1):39-45. doi:10.1002/jbmr.2315.Tsai J, Uihlein A, Burnett-Bowie S et al. Comparative Effects of Teriparatide, Denosumab, and Combination Therapy on Peripheral Compartmental Bone Density, Microarchitecture, and Estimated Strength: the DATA-HRpQCT Study. J Bone Miner Res. 2014;30(1):39-45. doi:10.1002/jbmr.2315.Neer R, Arnaud C, Zanchetta J et al. Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women With Osteoporosis. N Engl J Med. 2001 May 10;344(19):1434-41 DOI:10.1056/NEJM200105103441904Neer R, Arnaud C, Zanchetta J et al. Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women With Osteoporosis. N Engl J Med. 2001 May 10;344(19):1434-41 DOI:10.1056/NEJM200105103441904Gallagher J, Genant H, Crans G, Vargas S, Krege J. Teriparatide Reduces the Fracture Risk Associated with Increasing Number and Severity of Osteoporotic Fractures. The Journal of Clinical Endocrinology & Metabolism. 2005;90(3):1583-1587. doi:10.1210/jc.2004-0826Gallagher J, Genant H, Crans G, Vargas S, Krege J. Teriparatide Reduces the Fracture Risk Associated with Increasing Number and Severity of Osteoporotic Fractures. The Journal of Clinical Endocrinology & Metabolism. 2005;90(3):1583-1587. doi:10.1210/jc.2004-0826Orwoll E, Scheele W, Paul S et al. The Effect of Teriparatide [Human Parathyroid Hormone (1-34)] Therapy on Bone Density in Men With Osteoporosis. J Bone Miner Res. 2003;18(1):9-17. doi:10.1359/jbmr.2003.18.1.9.Orwoll E, Scheele W, Paul S et al. The Effect of Teriparatide [Human Parathyroid Hormone (1-34)] Therapy on Bone Density in Men With Osteoporosis. J Bone Miner Res. 2003;18(1):9-17. doi:10.1359/jbmr.2003.18.1.9.Saag K, Shane E, Boonen S et al. Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis. N Engl J Med. 2007 Nov 15;357(20):2028-39 DOI:10.1056/NEJMoa071408Saag K, Shane E, Boonen S et al. Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis. N Engl J Med. 2007 Nov 15;357(20):2028-39 DOI:10.1056/NEJMoa071408Liu CL, Lee HC, Chen CC, Cho DY. Head-to-head comparisons of bisphosphonates and teriparatide in osteoporosis: a meta-analysis. Clin Invest Med. 2017;40(3):E146-E157. doi: 10.25011/cim.v40i3.28394.Liu CL, Lee HC, Chen CC, Cho DY. Head-to-head comparisons of bisphosphonates and teriparatide in osteoporosis: a meta-analysis. Clin Invest Med. 2017;40(3):E146-E157. doi: 10.25011/cim.v40i3.28394.Wang YK, Qin SQ, Ma T, Song W, Jiang RQ, Guo JB, Li K, Zhang YM. Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2017;96(21):e6970. doi: 10.1097/MD.0000000000006970.Wang YK, Qin SQ, Ma T, Song W, Jiang RQ, Guo JB, Li K, Zhang YM. Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2017;96(21):e6970. doi: 10.1097/MD.0000000000006970.Kendler DL, Marin F, Zerbini CAF, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018 Jan 20;391(10117):230-240. doi: 10.1016/S0140-6736(17)32137-2Kendler DL, Marin F, Zerbini CAF, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018 Jan 20;391(10117):230-240. doi: 10.1016/S0140-6736(17)32137-2Body J, Gaich G, Scheele W et al. A Randomized Double-Blind Trial to Compare the Efficacy of Teriparatide [Recombinant Human Parathyroid Hormone (1–34)] with Alendronate in Postmenopausal Women with Osteoporosis. The Journal of Clinical Endocrinology & Metabolism. 2002;87(10):4528-4535. doi:10.1210/jc.2002-020334.Body J, Gaich G, Scheele W et al. A Randomized Double-Blind Trial to Compare the Efficacy of Teriparatide [Recombinant Human Parathyroid Hormone (1–34)] with Alendronate in Postmenopausal Women with Osteoporosis. The Journal of Clinical Endocrinology & Metabolism. 2002;87(10):4528-4535. doi:10.1210/jc.2002-020334.Hadji P, Zanchetta J, Russo L et al. Effect of teriparatide compared with risedronate on back pain and incident vertebral fractures in postmenopausal women with osteoporotic vertebral fractures. Bone. 2011;48:S82-S83. doi:10.1016/j.bone.2011.03.108.Hadji P, Zanchetta J, Russo L et al. Effect of teriparatide compared with risedronate on back pain and incident vertebral fractures in postmenopausal women with osteoporotic vertebral fractures. Bone. 2011;48:S82-S83. doi:10.1016/j.bone.2011.03.108.Miller PD, Shergy WJ, Body J, Chen P, Rohe ME, Krege JH.: Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate. J Rheumatology. 2005;32:1556-1562.Miller PD, Shergy WJ, Body J, Chen P, Rohe ME, Krege JH.: Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate. J Rheumatology. 2005;32:1556-1562.European Medicines Agency Press Office. EMEA recommends changes in the product Information for Protelos/Osseor due to the risk of severe hypersensitivity reactions. EMEA/417458/2007European Medicines Agency Press Office. EMEA recommends changes in the product Information for Protelos/Osseor due to the risk of severe hypersensitivity reactions. EMEA/417458/2007European Medicines Agency: Recommendation to restrict the use of Protelos/Osseor (strontium ranelate) 25 April 2013 EMA/258269/2013European Medicines Agency: Recommendation to restrict the use of Protelos/Osseor (strontium ranelate) 25 April 2013 EMA/258269/2013European Medicines Agency: Protelos/Osseor (strontium ranelate) to remain available but with futher restrictions 15 April 2014 EMA 235924/2014European Medicines Agency: Protelos/Osseor (strontium ranelate) to remain available but with futher restrictions 15 April 2014 EMA 235924/2014Bone H.G., Hosking D., Devogelaer J.P. et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. New Engl. J. Med. 2004;350(12):1189–99. doi: 10.1056/NEJMoa030897.Bone H.G., Hosking D., Devogelaer J.P. et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. New Engl. J. Med. 2004;350(12):1189–99. doi: 10.1056/NEJMoa030897.Adler R, El-Hajj Fuleihan G, Bauer D et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1):16-35. doi:10.1002/jbmr.2708Adler R, El-Hajj Fuleihan G, Bauer D et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1):16-35. doi:10.1002/jbmr.2708Black DM, Boonen S, Cauley JA, Cummings SR, Lippuner K, Leung PC, Martinez RLM, Ruzycky ME, Eastell R (2012a) Erratum: The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the horizon-pivotal fracture trial (PFT). J Bone Miner Res 27(12):2612,Black DM, Boonen S, Cauley JA, Cummings SR, Lippuner K, Leung PC, Martinez RLM, Ruzycky ME, Eastell R (2012a) Erratum: The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the horizon-pivotal fracture trial (PFT). J Bone Miner Res 27(12):2612,Black DM, Reid IR, Cauley JA, Cosman F, Leung PC, Lakatos P, Lippuner K, Cummings SR, Hue TF, Mukhopadhyay A, Tan M, Aftring RP, Eastell R (2015) The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: A randomized second extension to the HORIZON-pivotal fracture trial (PFT). J Bone Miner Res 30(5): 934-944Black DM, Reid IR, Cauley JA, Cosman F, Leung PC, Lakatos P, Lippuner K, Cummings SR, Hue TF, Mukhopadhyay A, Tan M, Aftring RP, Eastell R (2015) The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: A randomized second extension to the HORIZON-pivotal fracture trial (PFT). J Bone Miner Res 30(5): 934-944Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open- label extension. Lancet Diabetes Endocrinol 2017 5(7):513-23Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open- label extension. Lancet Diabetes Endocrinol 2017 5(7):513-23Bone HG, Bolognese MA, Yuenn CK, Kendler DL, Miller PD, Yang YC, Grazette L, Martin JS, Gallagher JC (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96(4):972- 980Bone HG, Bolognese MA, Yuenn CK, Kendler DL, Miller PD, Yang YC, Grazette L, Martin JS, Gallagher JC (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96(4):972- 980Bone HG, Chapurlat R, Brandi ML, et al. (2013) The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: Results from the FREEDOM extension. J Clin Endocrinol Metab 98(11):4483-4492Bone HG, Chapurlat R, Brandi ML, et al. (2013) The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: Results from the FREEDOM extension. J Clin Endocrinol Metab 98(11):4483-4492Anagnostis P, Paschou SA, Mintziori G, Ceausu I, Depypere H, Lambrinoudaki I, Mueck A, Perez-Lopez FR, Rees M, Senturk LM, Simoncini T, Stevenson JC, Stute P, Tremollieres FA, Goulis DG Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas, 2017, 101; 23030Anagnostis P, Paschou SA, Mintziori G, Ceausu I, Depypere H, Lambrinoudaki I, Mueck A, Perez-Lopez FR, Rees M, Senturk LM, Simoncini T, Stevenson JC, Stute P, Tremollieres FA, Goulis DG Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas, 2017, 101; 23030Белая Ж.Е., Bilezikian J.P., Ершова О.Б., и др. Возможности длительной терапии постменопаузального остеопороза: обзор результатов клинических исследований деносумаьа и резолюция совета экспертов российской ассоциации по остеопорозу (РАОП). Ж. Остеопороз и Остеопатии, 2018, Том 21, стр. 4-9Белая Ж.Е., Bilezikian J.P., Ершова О.Б., и др. Возможности длительной терапии постменопаузального остеопороза: обзор результатов клинических исследований деносумаьа и резолюция совета экспертов российской ассоциации по остеопорозу (РАОП). Ж. Остеопороз и Остеопатии, 2018, Том 21, стр. 4-9Brown J, Roux C, Törring O et al. Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial. J Bone Miner Res. 2013;28(4):746-752. doi:10.1002/jbmr.1808.Brown J, Roux C, Törring O et al. Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial. J Bone Miner Res. 2013;28(4):746-752. doi:10.1002/jbmr.1808.Popp A, Zysset P, Lippuner K. Rebound-associated vertebral fractures after discontinuation of denosumab—from clinic and biomechanics. Osteoporosis International. 2015;27(5):1917-1921. doi:10.1007/s00198-015-3458-6.Popp A, Zysset P, Lippuner K. Rebound-associated vertebral fractures after discontinuation of denosumab—from clinic and biomechanics. Osteoporosis International. 2015;27(5):1917-1921. doi:10.1007/s00198-015-3458-6.Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SAM (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): Extension of a randomised controlled trial. Lancet 386(9999):1147-1155Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SAM (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): Extension of a randomised controlled trial. Lancet 386(9999):1147-1155Ebina K, Hashimoto J, Kashii M, Hirao M, Kaneshiro S, Noguchi T, Tsukamoto Y, Yoshikawa H. The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis. J Bone Miner Metab. 2017 Jan;35(1):91-98. doi: 10.1007/s00774-015-0731-xEbina K, Hashimoto J, Kashii M, Hirao M, Kaneshiro S, Noguchi T, Tsukamoto Y, Yoshikawa H. The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis. J Bone Miner Metab. 2017 Jan;35(1):91-98. doi: 10.1007/s00774-015-0731-xDiez-Perez A, Adachi JD, Agnusdei D, Bilezikian JP, Compston JE, Cummings SR, Eastell R, Eriksen EF, Gonzales-Macies J, Liberman UA, Wahl DA, Seeman E, Kanis JA, Cooper C.: Treatment failure in osteoporosis. Osteoporosis Int. 2012;(23):2769-2774Diez-Perez A, Adachi JD, Agnusdei D, Bilezikian JP, Compston JE, Cummings SR, Eastell R, Eriksen EF, Gonzales-Macies J, Liberman UA, Wahl DA, Seeman E, Kanis JA, Cooper C.: Treatment failure in osteoporosis. Osteoporosis Int. 2012;(23):2769-2774Bousson V, Bergot C, Sutter B, Levitz P, Cortet B. Trabecular bone score (TBS): available knowledge, clinical relevance, and future prospects. Osteoporosis International. 2011;23(5):1489-1501. doi:10.1007/s00198-011-1824-6.Bousson V, Bergot C, Sutter B, Levitz P, Cortet B. Trabecular bone score (TBS): available knowledge, clinical relevance, and future prospects. Osteoporosis International. 2011;23(5):1489-1501. doi:10.1007/s00198-011-1824-6.International Society for Clinical Densitometry. 2013 Official Positions - Adult. http://www.iscd.org/ official-positions/2013-iscd-official-positions-adult. Ссылка активна на 12.05.2019.International Society for Clinical Densitometry. 2013 Official Positions - Adult. http://www.iscd.org/ official-positions/2013-iscd-official-positions-adult. Ссылка активна на 12.05.2019.Marcus R, Wang O, Satterwhite J, Mitlak B. The Skeletal Response to Teriparatide Is Largely Independent of Age, Initial Bone Mineral Density, and Prevalent Vertebral Fractures in Postmenopausal Women With Osteoporosis. J Bone Miner Res. 2003;18(1):18-23. doi:10.1359/jbmr.2003.18.1.18.Marcus R, Wang O, Satterwhite J, Mitlak B. The Skeletal Response to Teriparatide Is Largely Independent of Age, Initial Bone Mineral Density, and Prevalent Vertebral Fractures in Postmenopausal Women With Osteoporosis. J Bone Miner Res. 2003;18(1):18-23. doi:10.1359/jbmr.2003.18.1.18.Saag K, Zanchetta J, Devogelaer J et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis & Rheumatism. 2009;60(11):3346-3355. doi:10.1002/art.24879Saag K, Zanchetta J, Devogelaer J et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis & Rheumatism. 2009;60(11):3346-3355. doi:10.1002/art.24879British Orthopaedic Association and British Geriatrics Society. The care of patients with fragility fracture. 2007:15-50.British Orthopaedic Association and British Geriatrics Society. The care of patients with fragility fracture. 2007:15-50.Griffiths R, Alper J, Beckingsale A et al. Management of proximal femoral fractures 2011. Anaesthesia. 2011;67(1):85-98. doi:10.1111/j.1365-2044.2011.06957.x.Griffiths R, Alper J, Beckingsale A et al. Management of proximal femoral fractures 2011. Anaesthesia. 2011;67(1):85-98. doi:10.1111/j.1365-2044.2011.06957.x.Загородний Н.В., Голухов Г.Н., Волна А.А. и др. Диагностика и лечение переломов проксимального отдела бедра у лиц пожилого и старческого возраста. Метод. Рекомендации. Москва, РУДН, 2012.Загородний Н.В., Голухов Г.Н., Волна А.А. и др. Диагностика и лечение переломов проксимального отдела бедра у лиц пожилого и старческого возраста. Метод. Рекомендации. Москва, РУДН, 2012.Roche J. Effect of comorbidities and postoperative complications on mortality after hip fracture in elderly people: prospective observational cohort study. BMJ. 2005;331(7529):1374-0. doi:10.1136/bmj.38643.663843.55.Roche J. Effect of comorbidities and postoperative complications on mortality after hip fracture in elderly people: prospective observational cohort study. BMJ. 2005;331(7529):1374-0. doi:10.1136/bmj.38643.663843.55.Oliver D, Connelly J, Victor C et al. Strategies to prevent falls and fractures in hospitals and care homes and effect of cognitive impairment: systematic review and meta-analyses. BMJ. 2007;334(7584):82-82. doi:10.1136/bmj.39049.706493.55Oliver D, Connelly J, Victor C et al. Strategies to prevent falls and fractures in hospitals and care homes and effect of cognitive impairment: systematic review and meta-analyses. BMJ. 2007;334(7584):82-82. doi:10.1136/bmj.39049.706493.55Schmidt K, Hübscher M, Vogt L, et al. Influence of spinal orthosis on gait and physical functioning in women with postmenopausal osteoporosis// Der Orthopäde. — 2012. — Vol. 41. — No 3. — Р. 200–205Schmidt K, Hübscher M, Vogt L, et al. Influence of spinal orthosis on gait and physical functioning in women with postmenopausal osteoporosis// Der Orthopäde. — 2012. — Vol. 41. — No 3. — Р. 200–205Pfeifer M, Begerow B, Minne HW. Effects of a new spinal orthosis on posture, trunk strength, and quality of life in women with postmenopausal osteoporosis: a randomized trial. Am J Phys Med Rehabil. 2004; 83:177–186.Pfeifer M, Begerow B, Minne HW. Effects of a new spinal orthosis on posture, trunk strength, and quality of life in women with postmenopausal osteoporosis: a randomized trial. Am J Phys Med Rehabil. 2004; 83:177–186.Yuan Zhe Jin, Jae Hyup Lee Effect of Brace to Osteoporotic Vertebral Fracture: A Meta- Analysis//J Korean Med Sci 2016; 31: 1641-1649.Yuan Zhe Jin, Jae Hyup Lee Effect of Brace to Osteoporotic Vertebral Fracture: A Meta- Analysis//J Korean Med Sci 2016; 31: 1641-1649.Valentin GH, Pedersen LN, Maribo T. Wearing an active spinal orthosis improves back extensor strength in women with osteoporotic vertebral fractures // Prosthetics and orthotics international. — 2014. — Vol. 38. — No 3. — Р. 232–238Valentin GH, Pedersen LN, Maribo T. Wearing an active spinal orthosis improves back extensor strength in women with osteoporotic vertebral fractures // Prosthetics and orthotics international. — 2014. — Vol. 38. — No 3. — Р. 232–238Matussek J, Boluki D, Füssel S, Grifka. Orthotic methods for osteoporosis and osteoporotic vertebral fracture. J. Orthopade. 2010 Apr;39(4):387-96. [Article in German] doi: 10.1007/s00132-010-1596-2.Matussek J, Boluki D, Füssel S, Grifka. Orthotic methods for osteoporosis and osteoporotic vertebral fracture. J. Orthopade. 2010 Apr;39(4):387-96. [Article in German] doi: 10.1007/s00132-010-1596-2.Shariatzadeh H, Modaghegh BS, MD, Mirzaei A. The Effect of Dynamic Hyperextension Brace on Osteoporosis and Hyperkyphosis Reduction in Postmenopausal Osteoporotic Women. Arch Bone Jt Surg. 2017 May; 5(3): 181–185.Shariatzadeh H, Modaghegh BS, MD, Mirzaei A. The Effect of Dynamic Hyperextension Brace on Osteoporosis and Hyperkyphosis Reduction in Postmenopausal Osteoporotic Women. Arch Bone Jt Surg. 2017 May; 5(3): 181–185.Snow-Harter C, Bouxsein ML, Lewis BT, Carter DR, Marcus R. Effects of resistance and endurance exercise on bone mineral status of young women: a randomized exercise intervention trial. J Bone Miner Res. 1992; 7: 761-769Snow-Harter C, Bouxsein ML, Lewis BT, Carter DR, Marcus R. Effects of resistance and endurance exercise on bone mineral status of young women: a randomized exercise intervention trial. J Bone Miner Res. 1992; 7: 761-769Vainionpää A, Korpelainen R, Leppäluoto J, Jämsä T. Effects of high-impact exercise on bone mineral density: a randomized controlled trial in premenopausal women. Osteoporos Int. 2005;16(2):191-7Vainionpää A, Korpelainen R, Leppäluoto J, Jämsä T. Effects of high-impact exercise on bone mineral density: a randomized controlled trial in premenopausal women. Osteoporos Int. 2005;16(2):191-7Kelley G, Kelley K, Tran Z. Exercise and Lumbar Spine Bone Mineral Density in Postmenopausal Women: A Meta-Analysis of Individual Patient Data. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2002;57(9):M599-M604. doi:10.1093/gerona/57.9.m599.Kelley G, Kelley K, Tran Z. Exercise and Lumbar Spine Bone Mineral Density in Postmenopausal Women: A Meta-Analysis of Individual Patient Data. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2002;57(9):M599-M604. doi:10.1093/gerona/57.9.m599.Пигарова Е.А., Рожинская Л.Я., Белая Ж.Е., Дзеранова Л.К., Каронова Т.Л., Ильин А.В., Мельниченко Г.А., Дедов И.И. Клинические рекомендации Российской Ассоциации Эндокринологов по диагностике, лечению и профилактике дефицита витамина D у взрослых. Проблемы эндокринологии. 2016. Т. 62. № 4. С. 60-84Пигарова Е.А., Рожинская Л.Я., Белая Ж.Е., Дзеранова Л.К., Каронова Т.Л., Ильин А.В., Мельниченко Г.А., Дедов И.И. Клинические рекомендации Российской Ассоциации Эндокринологов по диагностике, лечению и профилактике дефицита витамина D у взрослых. Проблемы эндокринологии. 2016. Т. 62. № 4. С. 60-84Химический состав пищевых продуктов, используемых в Российской Федерации доступен по ссылке: http://web.ion.ru. Ссылка активна на 05.05.2016Химический состав пищевых продуктов, используемых в Российской Федерации доступен по ссылке: http://web.ion.ru. Ссылка активна на 05.05.2016Boonen S, Bischoff-Ferrari H, Cooper C et al. Addressing the Musculoskeletal Components of Fracture Risk with Calcium and Vitamin D: A Review of the Evidence. Calcified Tissue International. 2006;78(5):257-270. doi:10.1007/s00223-005-0009-8.Boonen S, Bischoff-Ferrari H, Cooper C et al. Addressing the Musculoskeletal Components of Fracture Risk with Calcium and Vitamin D: A Review of the Evidence. Calcified Tissue International. 2006;78(5):257-270. doi:10.1007/s00223-005-0009-8.Richy F, Dukas L, Schacht E. Differential Effects of D-Hormone Analogs and Native Vitamin D on the Risk of Falls: A Comparative Meta-Analysis. Calcified Tissue International. 2008;82(2):102-107. doi:10.1007/s00223-008-9102-0.Richy F, Dukas L, Schacht E. Differential Effects of D-Hormone Analogs and Native Vitamin D on the Risk of Falls: A Comparative Meta-Analysis. Calcified Tissue International. 2008;82(2):102-107. doi:10.1007/s00223-008-9102-0.Baber R, Panay N, Fenton A. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109-150. doi:10.3109/13697137.2015.1129166.Baber R, Panay N, Fenton A. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109-150. doi:10.3109/13697137.2015.1129166.Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principle results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principle results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333Ettinger B, Ensrud K, Wallace R et al. Effects of Ultralow-Dose Transdermal Estradiol on Bone Mineral Density: A Randomized Clinical Trial. Obstetrics & Gynecology. 2004;104(3):443-451. doi:10.1097/01.aog.0000137833.43248.79.Ettinger B, Ensrud K, Wallace R et al. Effects of Ultralow-Dose Transdermal Estradiol on Bone Mineral Density: A Randomized Clinical Trial. Obstetrics & Gynecology. 2004;104(3):443-451. doi:10.1097/01.aog.0000137833.43248.79.T.J. de Villiers, J.E. Hall, J.V. Pinkerton, S. Cerdas Perez, M. Rees, C. Yang, D.D. Pierroz Revised global Consensus Statement on Menopausal Hormone Therapy. J. Climacteric 2016 19:4; 313-315T.J. de Villiers, J.E. Hall, J.V. Pinkerton, S. Cerdas Perez, M. Rees, C. Yang, D.D. Pierroz Revised global Consensus Statement on Menopausal Hormone Therapy. J. Climacteric 2016 19:4; 313-315Kanis J.A., Johnell O., De Laet C., et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004; 35(2): 375-82.Kanis J.A., Johnell O., De Laet C., et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004; 35(2): 375-82.Klotzbuecher C.M., Ross P.D., Landsman P.B., et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Mineral Research 2000; 15(4): 721-39.Klotzbuecher C.M., Ross P.D., Landsman P.B., et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Mineral Research 2000; 15(4): 721-39.McLellan A, Reid D, Forbes K, et al. Effectiveness of strategies for the secondary prevention of osteoporotic fractures in Scotland (CEPS 99/03): NHS Quality Improvement Scotland. 2004.McLellan A, Reid D, Forbes K, et al. Effectiveness of strategies for the secondary prevention of osteoporotic fractures in Scotland (CEPS 99/03): NHS Quality Improvement Scotland. 2004.Akesson K., Marsh D., Mitchell P.J. et al. Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle. Osteoporos Int 2013; 24 (8): 2135-2152.Akesson K., Marsh D., Mitchell P.J. et al. Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle. Osteoporos Int 2013; 24 (8): 2135-2152.Hagino H., Sawaguchi T., Endo N., et al. The risk of a second hip fracture in patients after their first hip fracture. Calcif Tissue Int 2012; 90: 14-21.Hagino H., Sawaguchi T., Endo N., et al. The risk of a second hip fracture in patients after their first hip fracture. Calcif Tissue Int 2012; 90: 14-21.Dell R. Fracture prevention in Kaiser Permanente Southern California. Osteoporos Int. 2011; 22 Suppl 3: 457-60.Dell R. Fracture prevention in Kaiser Permanente Southern California. Osteoporos Int. 2011; 22 Suppl 3: 457-60.Nakayama A., Major G., Holliday E., Attia J., Bogduk N. Evidence of effectiveness of a fracture liaison service to reduce the re-fracture rate. Osteoporos Int. 2016; 27(3): 873-9.Nakayama A., Major G., Holliday E., Attia J., Bogduk N. Evidence of effectiveness of a fracture liaison service to reduce the re-fracture rate. Osteoporos Int. 2016; 27(3): 873-9.Marsh D., Akesson K., Beaton D. E. et al. Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporos Int. 2011; 22: 2051-2065.Marsh D., Akesson K., Beaton D. E. et al. Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporos Int. 2011; 22: 2051-2065.Ganda K., Mitchell P.J., Seibel M.J. Chapter 3 - Models of Secondary Fracture Prevention: Systematic Review and Metaanalysis of Outcomes. Secondary Fracture Prevention. An International Perspective. 2019. P. 33-62Ganda K., Mitchell P.J., Seibel M.J. Chapter 3 - Models of Secondary Fracture Prevention: Systematic Review and Metaanalysis of Outcomes. Secondary Fracture Prevention. An International Perspective. 2019. P. 33-62Ganda K, Puech M, Chen JS, Speerin R, Bleasel J, Center JR, et al. Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis. OsteoporosInt 2013;24(2):393–406.Ganda K, Puech M, Chen JS, Speerin R, Bleasel J, Center JR, et al. Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis. OsteoporosInt 2013;24(2):393–406.

The authors declare that there are no conflicts of interest present.